124 related articles for article (PubMed ID: 11954027)
1. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma.
Hecht JL; Lee BH; Pinkus JL; Pinkus GS
Cancer; 2002 Apr; 96(2):105-9. PubMed ID: 11954027
[TBL] [Abstract][Full Text] [Related]
2. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
3. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.
Hecht JL; Pinkus JL; Weinstein LJ; Pinkus GS
Am J Clin Pathol; 2001 Oct; 116(4):483-8. PubMed ID: 11601132
[TBL] [Abstract][Full Text] [Related]
4. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH; Hecht JL; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
Amin KM; Litzky LA; Smythe WR; Mooney AM; Morris JM; Mews DJ; Pass HI; Kari C; Rodeck U; Rauscher FJ
Am J Pathol; 1995 Feb; 146(2):344-56. PubMed ID: 7856747
[TBL] [Abstract][Full Text] [Related]
6. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
7. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
8. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
10. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
Dejmek A
Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
12. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
15. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
16. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
17. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
Afify AM; al-Khafaji BM
Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029
[TBL] [Abstract][Full Text] [Related]
19. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
20. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
Gulyás M; Hjerpe A
J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]